Roscovitine in B-chronic lymphocytic leukemia cells: High apoptosis-inducing efficacy and synergism with alemtuzumab Independent of the patients' pretreatment status

Haematologica

Volumn 92, Issue 9, 2007, Pages 1286-1288

  Weingrill, Eva ^a   Wölfler, Albert ^a   Strunk, Dirk ^a   Linkesch, Werner ^a   Sill, Heinz ^a   Liebmann, Peter M ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Alemtuzumab; Apoptosis; B CLL; Roscovitine; Synergism

Indexed keywords

ALEMTUZUMAB; BORTEZOMIB; CD52 ANTIGEN; DOXORUBICIN; FLAVOPIRIDOL; FLUDARABINE; MITOXANTRONE; ROSCOVITINE;

ADJUVANT THERAPY; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; B LYMPHOCYTE; CELL ISOLATION; CHEMOSENSITIVITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TREATMENT FAILURE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LEUKEMIA RELAPSE; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; UPREGULATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; COHORT STUDIES; DRUG SYNERGISM; FEMALE; GLYCOPROTEINS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MITOXANTRONE; PURINES; SALVAGE THERAPY;

EID: 36348933980     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10680     Document Type: Article

References (10)

1. Keating MJ, O'Brien S, Kontoyiannis D, Plunkett W, Koller C, Beran M, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43:1755-62.
2. Hahntow IN, Schneller F, Oelsner M, Weick K, Ringshausen I, Fend F, et al. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 2004; 18:747-55.
3. Alvi AJ, Austen B, Weston VJ, Fegan C, MacCallum D, Gianella-Borradori A, et al. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood 2005;105:4484-91.
4. Byrd JC, Peterson BL, Gabrilove J, Odenike OM, Grever MR, Rai K, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res 2005;11:4176-81.
5. Flinn TW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D, et al. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res 2005;29:1253-7.
6. Zent CS, Chen JB, Kurten RC, Kaushal GP, Marie Lacy H, Schichman SA. Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Res 2004; 28:495-507.
7. Golay J, Manganini M, Rambaldi A, Introna M. Effect of alemtuzumab on neoplastic B cells. Haematologica 2004; 89:1476-83.
8. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
9. Takahashi N, Li W, Banerjee D, Guan Y, Wada-Takahashi Y, Brennan MF, et al. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res 2002; 62: 6909-15.
10. Raje N, Kumar S, Hideshima T, Roccaro A, Ishitsuka K, Yasui H, et al. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 2005;106:1042-7.